louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06982248: The Proposed Study Aims to Investigate the Efficacy of Quercetin as an Adjunctive to Mechanical Debridement in Treatment of Periodontitis
Official title: Efficacy of Quercetin Loaded on Chitosan Nanoparticles Gel as an Adjunctive to Mechanical Debridement in Treatment of Periodontitis: Randomized Controlled Clinical Trial
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: PHASE2
Conditions: Periodontal Pocket
Lead sponsor: Mansoura University
Sponsor class: OTHER
First posted: 2025-05-21
Enrollment: 60
Sex: ALL
Minimum age (years): 25
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: FACTORIAL
Intervention model description: Group 1: Periodontitis patients treated by NSPT and chitosan nanoparticles gel loaded by quercetin.

Group 2: Periodontitis patients treated by NSPT and chitosan nanoparticles gel. Group 3: Periodontitis patients treated by NSPT only. Group 4: Periodontally healthy subjects.
Primary purpose: TREATMENT

Brief summary: the proposed study aims to investigate the effect of Quercetin in treatment of periodontitis patients

Detailed description: the proposed study aims to investigate the effect of Quercetin in treatment of periodontitis patients not having systemic diseases.the 2ry aim of study to estimate the neacular factor kabba B level in gingival crevicular fluids.

Eligibility criteria: Inclusion Criteria:

- Patients of both sexes with an age ranging between 25 and 55 years will be included in the study. Patients diagnosed as having periodontitis based on clinical and radiographic examinations will be included

Exclusion Criteria:

* Insulin dependent diabetes
* Thyroid disease
* Patients with sensitivity to the medication used in the study
* patients with a history of antibiotic use or anti-inflammatory drugs during the previous 3 months prior to the study will be excluded from the study.
* Additionally, patients with systemic diseases, smokers, pregnant and lactating patients, and patients not compliant with oral hygiene procedures will also be excluded

Primary outcomes:
measure: assessment clinical attachment level by UNC 15 periodontal probe
timeFrame: 12 weeks
Secondary outcomes:
measure: assessment of the gingival crevicular levels of NF-κB by Elisa kit
timeFrame: 12 weeks
Other outcomes:
Locations:
city: Aga
country: Egypt
facility: Faculty of Dentistry, Mansoura University
Study officials:
affiliation: Mansoura University
name: Jilan mohamed
role: STUDY_DIRECTOR
References:
Clinical trial NCT00327457: Coordinated Endoscopic Colorectal Cancer Screening
Official title: Coordinated Endoscopic Colorectal Cancer Screening
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Preventive Health Services
Keywords: colorectal cancer screening
sigmoidoscopy
colonoscopy
Lead sponsor: University of Pittsburgh
Sponsor class: OTHER
Collaborators: name: Association of Schools of Public Health
name: Centers for Disease Control and Prevention
First posted: 2006-05-18
Enrollment: 599
Sex: ALL
Minimum age (years): 50
Maximum age (years): 79
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: FACTORIAL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: The investigators aim to use a randomized design to test the effects of 1) tailored physician recommendations, relative to non-specific recommendations, and 2) coordinated physician office management systems on patient adherence to colorectal cancer screening recommendations.

Detailed description: The investigators aim to use a randomized design to test the effects of 1) tailored physician recommendations, relative to non-specific recommendations, and 2) coordinated physician office management systems on patient adherence to colorectal cancer screening recommendations.

To accomplish these aims, the investigators propose 1) to use existing physician practice-based computerized patient registration systems to define populations of 50 to 79 year-old pri-mary care patients, 2) to use mailed questionnaires to determine colorectal cancer risk factor status and prior colorectal cancer screening history, 3) to use responses from mailed questionnaires to identify persons not adhering to colorectal cancer screening guidelines, 4) to use computer driven algorithms to help physicians prepare and deliver individually tailored and written colorectal cancer screening recommendations, and 5) to develop, implement, and evaluate a centralized service for delivering high quality screening flexible sigmoidoscopy.

Eligibility criteria: Inclusion Criteria:

-

Exclusion Criteria:

* history of colorectal cancer or polyps
* flexible sigmoidoscopy within five years of enrollment
* barium enema within five years of enrollment
* colonoscopy within five years of enrollment

Primary outcomes:
measure: Medical record verified flexible sigmoidoscopy or colonoscopy
Secondary outcomes:
Other outcomes:
Locations:
city: Pittsburgh
country: United States
facility: University of Pittsburgh Cancer Institute
state: Pennsylvania
Study officials:
affiliation: University of Pittsburgh
name: Joel L. Weissfeld, MD MPH
role: PRINCIPAL_INVESTIGATOR
References:
citation: Ling BS, Schoen RE, Trauth JM, Wahed AS, Eury T, Simak DM, Solano FX, Weissfeld JL. Physicians encouraging colorectal screening: a randomized controlled trial of enhanced office and patient management on compliance with colorectal cancer screening. Arch Intern Med. 2009 Jan 12;169(1):47-55. doi: 10.1001/archinternmed.2008.519.
Clinical trial NCT06402448: Prevalence of Muscle and Nerve and Joint Pain
Official title: Prevalence of Muscle, Joint and Nerve Pain in Spinal Disorders.
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Muscle Pain
Joint Pain
Nerve Pain
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2024-05-07
Enrollment: 300
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patients from 18 to 6o years , both gender and any condition diagnosed by orthopedic physician with spinal disorders and pre and post operative patient may be included.

Brief summary: The purpose of the study is to provide adequate information about the percentage of the main tissue that causing pain in most common spinal disorders either it is muscular, nerve or joint in each spinal parts, that will provide the physical therapist with large data that can be helpful in differential diagnosis.


Eligibility criteria: Inclusion Criteria:

1. - patients from 18 to 60years
2. - both gender and any condition diagnosed by orthopedic physician with spinal disorders
3. - pre and post operative patient may be included.

Exclusion Criteria:

1. viscerogenic pain
2. cancer
3. psychogenic pain or psychogenic disorder
4. rheumatoid arthritis
5. fibromyalgia.

Primary outcomes:
measure: muscle pain
timeFrame: 5 months
measure: joint pain
timeFrame: 5 months
measure: nerve pain
timeFrame: 5 months
Secondary outcomes:
Other outcomes:
Locations:
city: Giza
country: Egypt
facility: Faculty of Physical Therapy Cairo University
Study officials:
References:
Clinical trial NCT03261648: Anxiety of Patient and His Partner During Admission to Emergency Department
Official title: Anxiety of Patient and His Partner During Admission to Emergency Department
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Anxiety
Emergencies
Lead sponsor: University Hospital, Toulouse
Sponsor class: OTHER
First posted: 2017-08-25
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: people admited in the emergency department and his partner

Brief summary: Evaluate and compare the impact of partner's stress in the pain of the patient admitted in the emergency department

Detailed description: Admission to an emergency department is a major source of anxiety for the patient. Anxiety plays not only a role in its emotional state but can also have consequences on the taking care of the patient and especially on the analgesic procedure.

Since pain is one of the first causes of emergency admission, patient anxiety should not be overlooked. In the emergency department, patient consults frequently, with his partner . Anxiety can also affect the partner, which may affect the patient. No studies have yet demonstrated this correlation.

This study will evaluate, the anxiety of both parties and show the presence or not of an influence of the partner's anxiety on the patient using a standardized questionnaire, the State-Trait Anxiety Inventory- form Y (STAI-Y).

Eligibility criteria: Inclusion Criteria:

* Admission to emergency department accompanied by his partner (lives in concubinage with the patient)
* Nurse patient's classification score up or equal to 3, 4 or 5
* Oral consent given to the inclusion by the patient and the partner
* Patient and partner Francophone or with a good understanding of French

Exclusion Criteria:

* Patient under a system of legal protection
* Non-Communicating Patient and partner
* Patient and partner unable to write
* Refusal of patient or partner
* Admission of the patient with shock treatment corresponding to the nurse patient's classification score 1 and 2

Primary outcomes:
measure: Compare the anxiety of the patient with that of his partner
timeFrame: day 1
Secondary outcomes:
measure: Study the link between the patient's and his partner's anxiety
timeFrame: day 1
measure: Evaluate the link between the patient's anxiety and the patient's pain
timeFrame: day 1
Other outcomes:
Locations:
city: Toulouse
country: France
facility: University Hospital of Toulouse
Study officials:
affiliation: University Hospital of Toulouse, Toulouse, France
name: Vincent BOUNES, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01379248: Effect of Thrombus Aspiration in Patients With Myocardial Infarction Presenting Late After Symptom Onset
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Myocardial Infarction
Lead sponsor: University of Leipzig
Sponsor class: OTHER
First posted: 2011-06-23
Enrollment: 152
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to examine the benefit of thrombus aspiration in patients with ST-elevation myocardial infarction presenting late after symptom onset.


Eligibility criteria: Inclusion Criteria:

* ST-elevation myocardial infarction \>12 and \<48 hours after symptom onset
* age 18 to 90 years
* informed consent

Exclusion Criteria:

* prior fibrinolysis
* severe comorbidities with limited life expectancy
* pregnancy
* patient unable to give informed consent
* participation in another trial
* contraindications for heparin, aspirin or thienopyridines
* contraindications for cardiac magnetic resonance examination

Primary outcomes:
measure: Microvascular obstruction (cardiac magnetic resonance imaging)
timeFrame: 1-4 days after randomization
Secondary outcomes:
Other outcomes:
Locations:
city: Leipzig
country: Germany
facility: University of Leipzig Heart Center
Study officials:
References:
citation: Desch S, Stiermaier T, de Waha S, Lurz P, Gutberlet M, Sandri M, Mangner N, Boudriot E, Woinke M, Erbs S, Schuler G, Fuernau G, Eitel I, Thiele H. Thrombus Aspiration in Patients With ST-Segment Elevation Myocardial Infarction Presenting Late After Symptom Onset. JACC Cardiovasc Interv. 2016 Jan 25;9(2):113-22. doi: 10.1016/j.jcin.2015.09.010.
Clinical trial NCT03972748: Use Of Oral Itraconazole In Patients With Locally Limited Basocellular Carcinoma Of Skin.
Official title: Evaluation Of The Treatment With Oral Itraconazole In Patients With Basocellular Carcinoma Of Skin, Locally Limited Disease.
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Basal Cell Carcinoma
Hedgehog Pathway
Keywords: Itraconazole
Lead sponsor: Hospital de Clinicas de Porto Alegre
Sponsor class: OTHER
First posted: 2019-06-04
Enrollment: 28
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Patients with localized basocellular carcinoma of the skin, will receive oral Itraconazole, 200 mg twice daily, for 60 days, prior to curative intent surgery.

Detailed description: Patients with localized basocellular carcinoma of the skin, will receive oral Itraconazole, 200 mg once daily, for 60 days, before surgery with curative intent.

Tumor area regression will be measured through dermatologic evaluation and photographic documentation on baseline and at the end of the 60 day treatment period.

The activity of the Hedgehog pathway will be measured on tissue samples obtained at the time of diagnosis and at the time of curative intent surgery, through the measuring of the Ki67 index.

Eligibility criteria: Inclusion Criteria:

* Patients with diagnosis of Basocellular Carcinoma (BCC) of the Skin, histologically confirmed.
* At least one BCC lesion with 10 mm in the longest diameter
* Disease amenable to surgical intervention with curable intent.
* Signed Informed Consent
* PS ECOG 0 to 3

Exclusion Criteria:

* Chronic renal disease, with a glomerular filtration rate of less than 30 ml/min
* Acute or chronic liver disease, as measured by: total bilirubin \> than 1.5 x ULN and AST and ALT \> than 5 x ULN.
* Symptomatic cardiac insufficiency or an ejection fraction lower than 50% measured through echocardiography,
* Other active malignancies in the last year.
* Uncontrolled systemic hypertension,
* Any chronic infections such as tuberculosis, viral hepatitis and HIV.
* Pregnancy, suspected or confirmed.
* Known intolerance to the use of Itraconazole.

Primary outcomes:
measure: clinical response
timeFrame: 60 days
measure: hedgehog pathway activity
timeFrame: 60 days
Secondary outcomes:
Other outcomes:
Locations:
city: Porto Alegre
country: Brazil
facility: Hospital de Clínicas de Porto Alegre
state: RS
Study officials:
affiliation: Hospital de Clinicas de Porto Alegre
name: Renato M Bakos, Ph. D.
role: STUDY_CHAIR
References:
Clinical trial NCT00725348: An Open-Label, Multi-Center Trial in the Treatment of Subjects With Moderate to Severe Plaque Type Psoriasis
Official title: An Open-Label, Multi-Center Pilot Trial to Assess the Efficacy and Safety of Oral R115866 in the Treatment of Subjects With Moderate to Severe Plaque Type Psoriasis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Psoriasis
Keywords: Psoriasis
Lead sponsor: GlaxoSmithKline
Sponsor class: INDUSTRY
First posted: 2008-07-30
Enrollment: 19
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is a study of a new oral drug used for the treatment of psoriasis. All subjects will get active medication, there is no placebo arm.


Eligibility criteria: Inclusion Criteria:

* Male or female of non-childbearing potential (at least 2 years post-menopausal or undergone successful surgical sterilization at least 1 year before inclusion)
* Presence of moderate to severe plaque psoriasis with a PASI of at least 5

Exclusion Criteria:

* Pustular, guttate or other non-plaque forms of psoriasis or psoriatic arthritis
* Significant coexisting hepatic, renal, or bone marrow disease, hyperlipidemia, chronic pancreatitis, osteoporosis, or a history indicating adrenal cortex dysfunction or any other serious disease (including cancer and subjects known to be HIV positive)
* History of heart failure, myocardial infarction within the past six months, cardiac arrhythmia, or under treatment for heart disorders
* Clinically significant abnormal ECG-intervals or morphology of the ECG; QT or QTc \>470 ms in females or \>450 ms in males
* Use of vitamin A (\>1000 µg/day), phenytoin, carbamazepine, warfarin, rifampicin, tetracyclines, ketoconazole, itraconazole, astemizole, terfenadine, cisapride, anti-psychotics, anti-depressants, lithium, antimalarials, alpha-blocking drugs, angiotensin-converting enzyme inhibitors, cyclosporin A, glucocorticosteroids and non-steroidal anti-inflammatory drugs, non-potassium-sparing diuretics
* Previous use of any systemic immunomodulatory therapy (biologicals) or psoriasis vaccine
* Use of other systemic therapy for psoriasis (e.g. PUVA, systemic steroids, cyclosporin A, methotrexate, retinoids) within four weeks prior to Visit 2
* Use of UV therapy or excessive UV exposure or topical therapy for psoriasis other than bland emollients within two weeks prior to Visit 2

Primary outcomes:
measure: PASI Scores
timeFrame: Various Visits
Secondary outcomes:
Other outcomes:
Locations:
city: Maastricht
country: Netherlands
facility: Academisch Ziekenhuis Maastricht
city: Nijmegen
country: Netherlands
facility: Universitair Medisch Centrum Nijmegen Sint Radboud
Study officials:
affiliation: University of Nijmegen, Maastricht, The Netherlands
name: Prof. P. van de Kerkhof, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00347048: Tacrolimus (FK506) Study in Moderate to Severe Refractory Ulcerative Colitis Patients
Official title: Tacrolimus (FK506) P-III Placebo-Controlled Double-Blind Study in Moderate to Severe Refractory Ulcerative Colitis Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Ulcerative Colitis
Keywords: Ulcerative colitis
tacrolimus
FK506
treatment outcome
Lead sponsor: Astellas Pharma Inc
Sponsor class: INDUSTRY
First posted: 2006-07-04
Enrollment: 62
Sex: ALL
Minimum age (years): 16
Maximum age (years): 64
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study consists of a 2-week placebo-controlled double-blind inter-group efficacy study in moderate to severe refractory ulcerative colitis (UC) patients followed by a maximum of 12-week open-label efficacy and safety study in responders.


Eligibility criteria: Inclusion Criteria:

* Moderate to severe refractory UC patients
* Disease activity: more than 4 times of stool a day, bloody stool, moderate to severe endoscopic finding
* Steroid resistance or dependence to meet at least one of the following condition:no efficacy with more than 40mg/day or 1mg/kg/day of steroid over at least 1 week, no efficacy with 30-40mg/day of steroid over at least 2 weeks,exacerbation along with steroid reduction

Exclusion Criteria:

* Mild or fulminant type
* Renal failure patients, hepatic failure patients
* Patients taking 6-mercaptopurine, cyclosporin or other immunosuppressants within 12 weeks prior to entry
* Patients who received LCAP or GCAP within 2 weeks prior to entry
* Patients who changed the dose of steroid or started steroid within 2 weeks prior to entry.
* Patients who changed the dose of steroid or started steroid within 1 week prior to entry in case they received more than 40 mg/ day or 1mg/kg/day of steroid just before the study.

Primary outcomes:
measure: Improvement of Disease activity index score (DAI score)
timeFrame: 2 Weeks
Secondary outcomes:
measure: Changes of DAI score ( Total & each item)
timeFrame: 2 Weeks
measure: Changes of clinical severity and symptom
timeFrame: 2 Weeks
measure: Endoscopic finding
timeFrame: 2 Weeks
measure: Patients impression
timeFrame: 2 Weeks
measure: Amount of steroid
timeFrame: 2 Weeks
Other outcomes:
Locations:
city: Chubu region
country: Japan
city: Hokkaido region
country: Japan
city: Kansai region
country: Japan
city: Kanto region
country: Japan
city: Kyushu region
country: Japan
city: Shin'etsu region
country: Japan
Study officials:
affiliation: Astellas Pharma Inc
name: Use Central Contact
role: STUDY_CHAIR
References:
Clinical trial NCT03758248: The Influence of Gene Polymorphism on Clinical Outcomes in Patients Undergoing PCI
Official title: The Influence of Gene Polymorphism on Clinical Outcomes in Patients Undergoing PCI
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Antiplatelet Therapy
CYP2C19 Polymorphism
Keywords: Genotype-guided therapy
CYP2C19 Polymorphism
Lead sponsor: Beijing Anzhen Hospital
Sponsor class: OTHER
First posted: 2018-11-29
Enrollment: 12000
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: OTHER
Sampling method: PROBABILITY_SAMPLE
Study population: PCI patients in Beijing Anzhen Hospital from August 2018 to August 2019

Brief summary: Dual antiplatelet therapy with aspirin and thienopyridines is an essential treatment in patients undergoing percutaneous coronary intervention (PCI). However, despite intensified antiplatelet treatment, some of the patients undergoing PCI develop thrombotic stent occlusion, suggesting incomplete platelet inhibition due to thienopyridine resistance. Some patients develop bleeding event because of the improper dosage and covariation. This observational study is designed for clarifying the Influence of gene polymorphism on clinical outcomes in patients undergoing PCI.

Detailed description: Patients undergoing PCI who received dual antiplatelet therapy with both aspirin (100mg) and P2Y12 inhibitors in standard dosage were enrolled. Investigators examined plasma biomarkers for platelet activation and DNA in those patients, and then analyzed the CYP2C19 genetic polymorphism to examine the influence of this genetic variation on the several biomarkers for platelet activation and bleeding event.

Eligibility criteria: Inclusion Criteria:

1. The patients undergoing PCI
2. More than 18 years old
3. Treated with aspirin and P2Y12 inhibitors (clopidogrel or ticagrelor)

Exclusion Criteria:

Inability to provide written informed consent

Primary outcomes:
measure: Patients with treatment-related major bleeding event as assessed by the Bleeding Academic Research Consortium (BARC) bleeding criteria
timeFrame: up to 24 months
Secondary outcomes:
measure: Major adverse cardiac events (MACE)
timeFrame: up to 24 months
Other outcomes:
Locations:
city: Beijing
country: China
facility: Beijing Anzhen Hospital
state: Beijing
Study officials:
affiliation: Beijing Anzhen Hospital
name: Yujie Zhou, PhD,MD
role: PRINCIPAL_INVESTIGATOR
References: